Preliminary Study of the Relationship between Osteopontin and Relapsed Hodgkin’s Lymphoma
-
Published:2023-12-21
Issue:1
Volume:12
Page:31
-
ISSN:2227-9059
-
Container-title:Biomedicines
-
language:en
-
Short-container-title:Biomedicines
Author:
De Re Valli1ORCID, Lopci Egesta2ORCID, Brisotto Giulia1ORCID, Elia Caterina3, Mussolin Lara45ORCID, Mascarin Maurizio3ORCID, d’Amore Emanuele Stefano Giovanni6,
Affiliation:
1. Immunopatologia e Biomarcatori Oncologici, CRO Aviano, National Cancer Institute, Istituto di Ricovero e Cura a Carattere Scientifico, IRCCS, 33081 Aviano, Italy 2. Nuclear Medicine Unit, IRCCS—Humanitas Research Hospital, Rozzano, 20089 Milano, Italy 3. AYA Oncology and Pediatric Radiotherapy Unit, CRO Aviano, National Cancer Institute, Istituto di Ricovero e Cura a Carattere Scientifico, IRCCS, 33081 Aviano, Italy 4. Pediatric Hemato-Oncology Unit, Department of Women’s and Children’s Health, University of Padua, 35122 Padua, Italy 5. Clinica di Oncoematologia Pediatrica, Azienda Ospedaliera—Università di Padova, 35128 Padova, Italy 6. Department of Pathology, San Bortolo Hospital, 36100 Vicenza, Italy
Abstract
The primary objective of this study was to investigate the potential role of tissue osteopontin, also known as secreted phosphoprotein 1 (SPP1), as a contributing factor to an unfavorable prognosis in classical Hodgkin’s lymphoma (HL) patients who received the same treatment protocol. The study involved 44 patients aged 4–22 years, with a median follow-up period of 3 years. Patients with higher levels of SPP1 were associated with tissue necrosis and inflammation, and there was a trend toward a poorer prognosis in this group. Before therapy, we found a correlation between positron emission tomography (PET) scans and logarithmic SPP1 levels (p = 0.035). However, the addition of SPP1 levels did not significantly enhance the predictive capacity of PET scans for recurrence or progression. Elevated SPP levels were associated with tissue mRNA counts of chemotactic and inflammatory chemokines, as well as specific monocyte/dendritic cell subtypes, defined by IL-17RB, PLAUR, CXCL8, CD1A, CCL13, TREM1, and CCL24 markers. These findings contribute to a better understanding of the potential factors influencing the prognosis of HL patients and the potential role of SPP1 in the disease. While the predictive accuracy of PET scans did not substantially improve during the study, the results underscore the complexity of HL and highlight the relationships between SPP1 and other factors in the context of HL relapse.
Funder
Italian Ministry of Health
Subject
General Biochemistry, Genetics and Molecular Biology,Medicine (miscellaneous)
Reference49 articles.
1. (2023, August 08). SEER Cancer Statistics Review, 1975–2017, Available online: https://seer.cancer.gov/csr/1975_2017/index.html. 2. AIRTUM Working Group, CCM, and AIEOP Working Group (2013). Italian Cancer Figures, Report 2012: Cancer in Children and Adolescents. Epidemiol. Prev., 37, 1–225. 3. Burnelli, R., Fiumana, G., Rondelli, R., Pillon, M., Sala, A., Garaventa, A., D’Amore, E.S.G., Sabattini, E., Buffardi, S., and Bianchi, M. (2020). Comparison of Hodgkin’s Lymphoma in Children and Adolescents. A Twenty Year Experience with MH’96 and LH2004 AIEOP (Italian Association of Pediatric Hematology and Oncology) Protocols. Cancers, 12. 4. De Re, V., Repetto, O., Mussolin, L., Brisotto, G., Elia, C., Lopci, E., d’Amore, E.S.G., Burnelli, R., and Mascarin, M. (2022). Promising Drugs and Treatment Options for Pediatric and Adolescent Patients with Hodgkin Lymphoma. Front. Cell Dev. Biol., 10. 5. Late Effects of Radiation Therapy in Pediatric Patients and Survivorship;Palmer;Pediatr. Blood Cancer,2021
|
|